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Abstract
Introduction Medroxyprogesterone acetate (MPA), the major
progestin used for oral contraception and hormone replacement
therapy, has been implicated in increased breast cancer risk. Is
this risk due to its progestational or androgenic properties? To
address this, we assessed the transcriptional effects of MPA as
compared with those of progesterone and dihydrotestosterone
(DHT) in human breast cancer cells.
Method A new progesterone receptor-negative, androgen
receptor-positive human breast cancer cell line, designated Y-
AR, was engineered and characterized. Transcription assays
using a synthetic promoter/reporter construct, as well as
endogenous gene expression profiling comparing
progesterone, MPA and DHT, were performed in cells either
lacking or containing progesterone receptor and/or androgen
receptor.
Results In progesterone receptor-positive cells, MPA was
found to be an effective progestin through both progesterone
receptor isoforms in transient transcription assays. Interestingly,
DHT signaled through progesterone receptor type B.
Expression profiling of endogenous progesterone receptor-
regulated genes comparing progesterone and MPA suggested
that although MPA may be a somewhat more potent progestin
than progesterone, it is qualitatively similar to progesterone. To
address effects of MPA through androgen receptor, expression
profiling was performed comparing progesterone, MPA and
DHT using Y-AR cells. These studies showed extensive gene
regulatory overlap between DHT and MPA through androgen
receptor and none with progesterone. Interestingly, there was
no difference between pharmacological MPA and physiological
MPA, suggesting that high-dose therapeutic MPA may be
superfluous.
Conclusion Our comparison of the gene regulatory profiles of
MPA and progesterone suggests that, for physiologic hormone
replacement therapy, the actions of MPA do not mimic those of
endogenous progesterone alone. Clinically, the complex
pharmacology of MPA not only influences its side-effect profile;
but it is also possible that the increased breast cancer risk and/
or the therapeutic efficacy of MPA in cancer treatment is in part
mediated by androgen receptor.
Introduction
Synthetic progestins have been in use since the 1950s. Today
more than 15 million women use them either in combination
oral contraceptives or for hormone replacement therapy (HRT)
[1]. Although progestins are added to estrogens because they
significantly lower the risk for endometrial cancer, HRT is often
not started or discontinued prematurely because of breast
cancer fears. Recent data from the Women's Health Initiative
[2,3] suggest slight increases in relative risk (RR) for develop-
ing invasive breast cancer (RR 1.26), cardiovascular disease
(RR 1.22), pulmonary emboli (RR 2.13), and dementia (RR
2.05) in women on HRT containing continuous dosing of con-
jugated equine estrogen and medroxyprogesterone acetate
(MPA). This led to premature termination of the estrogen +
MPA arm of the trial. The estrogen-only arm was recently ter-
minated and its analysis, although indicating an increased risk
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for stroke (hazard ratio 1.39), showed no increase in breast
cancer risk (hazard ratio 0.77) [4]. These and other data [5]
implicate the progestin component in the increased breast
cancer risk observed with estrogen + MPA [6].
Most synthetic progestins are derived from either testosterone
or 17α-hydroxyprogesterone (Fig. 1). MPA (Depo-Provera
UpJohn, St Louis, MO and Provera UpJohn, St Louis, MO) is a
17α-hydroxyprogesterone derivative and is the most common
HRT progestin in use in the USA [7]. It is used in place of pro-
gesterone because of its longer half-life [7]. Synthetic pro-
gestins in general were originally selected based on the
similarity of their pharmacology to that of progesterone [7].
However, although modern molecular information is available
about the genes regulated by progesterone [8,9], there are no
global data on the genes regulated by synthetic progestins.
Recently, Nilsen and Brinton [10] reported differences
between the abilities of MPA and progesterone to activate
mitogen-activated protein kinase signaling in hippocampal
neurons. Progesterone and MPA also differ in their ability to
express vascular cell adhesion molecule-1 in human vascular
endothelial cells [11]. Furthermore, in addition to their proges-
tational effects, and unlike natural progesterone, synthetic pro-
gestins often bind other steroid receptors including those for
androgens (androgen receptors [AR]) and glucocorticoids
(glucocorticoid receptors [GR]) [12,13]. Thus, depending on
the dose and tissue, it is possible that synthetic progestins dif-
fer in their gene regulatory profile compared with
progesterone.
Progestins signal mainly though progesterone receptors (PR),
which are members of the steroid receptor family of nuclear
receptors. There are two naturally occurring human PR iso-
forms, PR-A and PR-B [14,15], which are identical except for
164 additional amino acids at the amino-terminus of PR-B. For
this reason, the two PR vary in their ability to activate transcrip-
tion on exogenous [16-20] and endogenous promoters, with
PR-B being 10 times more active than PR-A [8,9,19]. Ratios
of PR-A to PR-B ratios vary in different tissues, physiological
states, and breast cancers [21-24]. The normal human breast
contains equimolar amounts of PR-A and PR-B, but ratios of
PR-A to PR-B are dysregulated in more than 70% of advanced
breast cancers [25]. Excess PR-A levels correlate with poorer
disease-free survival and more rapid relapse following
tamoxifen treatment [26]. Ligand binding leads to PR activa-
tion, dimerization, and binding of dimers to promoters at pro-
gesterone responsive elements (PREs), followed by
interaction with coregulators and altered transcription [27].
PREs are also consensus binding sites for other nuclear
receptors, including AR and GR [28-30]. In additional, given
the 60% similarity in the ligand binding domains between AR
and PR, some ligands – including MPA – can bind both steroid
receptors [31].
In vivo, progesterone and most natural steroid hormones are
actively metabolized in the liver [32]. In breast cancer cells in
vitro, progesterone at physiologic concentrations (10–20
nmol/l) is sufficient to activate all receptors [33]. Physiologic
concentrations of progesterone have a half-life of 2–4 hours in
cells, and even at pharmacologic concentrations (1 µmol/l)
progesterone is still entirely metabolized within 18 hours to its
final metabolic product, namely 5α-pregnan-3β, 6α-diol-20-
one it's correct[34]. In contrast, under the same in vitro condi-
tions synthetic progestins, including MPA, megestrol acetate,
R5020, and the antiprogestin RU486, are not metabolized at
all [35], and 20–40% of dihydrotestosterone (DHT) remains
Figure 1
Chemical structures of progesterone, MPA, R5020 and DHT Chemical structures of progesterone, MPA, R5020 and DHT. The pharmaceutical name and manufacturer are shown italic text. DHT, dihydrotesto-
sterone; MPA, medroxyprogesterone acetate.Available online http://breast-cancer-research.com/content/7/6/R1036
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unmetabolized at 18 hours [34]. Specifically with regard to
MPA, the active form is the parent compound MPA itself [7].
Serum levels of MPA needed for contraceptive efficacy are
about 2 nmol/l (1 ng/ml) [36] and for HRT the range is 0.02–
0.2 nmol/l (0.01–0.1 ng/ml); these levels are considered to be
'physiologic'. In addition to its use in contraception and HRT,
MPA is also commonly used to treat endometrial cancer and
as a second line agent to treat breast cancer [37]; for these
indications its serum levels are approximately 0.14–1.7 µmol/
l (55–650 ng/ml) [38,39], which are 'pharmacologic' concen-
trations. Thus, depending on need, there is a wide range of
concentrations at which MPA is used clinically. MPA also has
known glucocorticoid [40,41] and androgenic [40,42,43]
activities in breast cancer cells. It exhibits moderate relative
binding affinity (58%) to GR and a slightly slower relative bind-
ing affinity to AR (36%) [44].
The goal of the present study was to evaluate the transcrip-
tional similarities and differences between physiologic and
pharmacologic progesterone and MPA concentrations, focus-
ing on the abilities of these hormones to signal through PR,
AR, and GR. Under the conditions tested, we found that – in
addition to its progestational actions – MPA is an active andro-
gen. We therefore defined global gene regulatory patterns of
MPA on PR and AR and showed that at physiologic concen-
trations and early time points MPA is a dual function hormone.
Like progesterone, it is a good progestin; unlike progesterone,
it is also a strong androgen in breast cancer cells. These find-
ings may have important clinical implications for physicians
counseling women regarding the use of MPA in HRT.
Materials and methods
Cell lines and culture
The T47Dco breast cancer cell line (PR-A+ and PR-B+), its PR-
negative T47D-Y subline, and construction of T47D-YB (PR-
B+) and T47D-YA (PR-A+) cell lines were previously described
[45,46]. Construction of HeLa cervical carcinoma cells stably
expressing flag tagged PR-A (HeLa-A) or PR-B (HeLa-B) were
also previously described [47]. To construct Y-AR cells, PR-
negative T47D-Y cells were electroporated with a G418
resistance plasmid along with the pCMV5-AR vector contain-
ing the complete sequence for human AR [48] (a kind gift from
E Wilson). Colonies were picked and maintained under G418
selection. Transient transfection with a PRE2/luciferase
reporter [49] and western blotting for AR were used to screen
19 clones, using T47D-Y cells transiently transfected with
both AR and the reporter as a positive control. For this, cells
were treated with ethanol or 1 µmol/l DHT and harvested at 20
hours, and relative luciferase activity was assessed. Three
positive clones were identified, and clone 17 (renamed Y-AR)
was used for further experiments. Cells were routinely pas-
saged in minimum essential medium with Earle's salts contain-
ing L-glutamine (292 µg/l) buffered with sodium bicarbonate
(2.2 µg/l), insulin (6 ng/ml), and 7.5% fetal calf serum. Cells
stably expressing receptors – YB, Y-AR, HeLa-A and HeLa-B
– were also cultured in 200 µg/ml G418.
Transcription assays
Progesterone and MPA were obtained from Sigma (St Louis,
MO, USA) and DHT was a gift from M Wierman (Veterans
Affairs Medical Center, Denver, CO, USA). Cells were placed
in minimum essential medium containing 5% twice dextran-
coated charcoal (DCC) stripped serum for 24 hours. They
were then transfected by electroporation at 220 V and 950 µF
with the PRE2/TATA-luciferase reporter along with CMV/
Renilla as an internal control, and with PR-B, PR-A, or AR
expression vectors as appropriate. Cells were plated at a den-
sity of 106 cells/35 mm dish and treated with increasing con-
centrations of hormones in triplicate. The cells were harvested
20 hours later, lysed in 1× lysis buffer (Promega, San Diego,
CA, USA) and luciferase and Renilla activity (Promega, Madi-
son, WI, USA) were measured. Prism v3.0 (GraphPad Soft-
ware, San Diego, CA, USA) was used for all data analysis.
Statistical analysis was performed using the Student's t-test.
Error bars reflect the standard error of the mean. HeLa wild-
type, HeLa-A, and HeLa-B cells were plated in 60 mm dishes
at 120,000 cells/dish in 3 ml of 5% twice DCC-stripped
serum containing medium. HeLa cells stably expressing PR-A
or PR-B were transfected with the PRE2/TATA-luciferase (1
µg/dish) and SV40/Renilla (10 ng/dish) constructs using
CaPO4. After overnight incubation at 37°C, precipitate was
washed out and cells were treated with 0.01 nmol/l to 1 µmol/
l R5020, MPA, or DHT dissolved in ethanol. Cells were har-
vested at 20 hours, lysed in 1× lysis buffer, and luciferase and
Renilla activity measured. Wild-type HeLa cells were also
transfected with an AR expression vector (50 ng/dish) as
appropriate.
Expression profiling
T47Dco, Y, and Y-AR cells in log phase were placed in 5%
twice DCC-stripped serum containing medium for 24 hours
and then treated with vehicle, or 10 nmol/l progesterone or
MPA for 6 hours. Y-AR cells were additionally treated with 1
µmol/l MPA and 10 nmol/l DHT. Experiments were done in
triplicate for each cell line and treatment group using time sep-
arated samples. AR and/or PR protein levels were monitored
by immunoblotting. Cells were harvested and washed, and
total RNA was isolated using Rneasy Midi Kit (Qiagen, Valen-
cia, CA, USA). RNA integrity was confirmed using an Agilent
Bioanalyzer (Agilent, Palo Alto, CA, USA). RNA was prepared
according to the Affymetrix Expression Analysis Technical
Manual (Affymetrix, Inc., Santa Clara, CA, USA). Briefly, first
and second strand cDNA synthesis was performed followed
by clean up of double-stranded cDNA. Antisense cRNA was
biotin labeled for 4 hours in an in vitro transcription reaction,
and 20 µg biotin-labeled cRNA was fragmented and hybrid-
ized. Microarray analysis was performed using Affymetrix gene
chips (HuFL-U133 plus2). Data were analyzed using Gene
Spring version 6.0 (Silicon Genetics, San Carlos, CA, USA)Breast Cancer Research    Vol 7 No 6    Ghatge et al.
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and GCOS (Affymetrix, Inc.). Each treatment group was com-
pared with ethanol treatment. Low-dose and high-dose MPA
treatments were additionally compared with each other.
Statistical significance (P < 0.05) for a 2.0-fold change was
assessed by one-way analysis of variance. Dendrograms were
generated in Gene Spring version 6.0 (Silicon Genetics) using
hierarchical clustering, and similarity was measured using a
distance correlation [50].
Androgen receptor immunoblotting
Whole cell extracts were prepared in radioimmune precipita-
tion buffer with protease inhibitors, as described previously
[47]. Extracts were resolved on a 7.5% denaturing polyacryla-
mide gel, transferred to nitrocellulose, and blocked and
probed for AR with a 1:3000 dilution of AR antibody (PG-21;
Upstate Biotechnology, Lake Placid, NY, USA). Following
incubation with a horseradish peroxidase-conjugated goat
anti-rabbit secondary antibody, protein bands were visualized
by enhanced chemiluminescence (Amersham Biosciences
Pharmacia Biotech, Arlington Heights, IL).
Immunocytochemistry/confocal microscopy
Sterile coverslips were placed into 35 mm dishes along with
Y-AR cells at a density of 60,000 cells/35 mm dish in 5%
twice DCC-stripped serum overnight. Cells were treated with
ethanol or 1 µmol/l DHT for 30 min, 2 hours and 20 hours, and
fixed in a 70% methanol/30% acetone mixture for 5 min. Cov-
erslips were rinsed in phosphate-buffered saline (PBS),
blocked in 10% normal goat serum/PBS for 1 hour at room
temperature, and washed twice in PBS. Coverslips were
probed with PG-21 diluted to 0.5 µg/ml in 1% normal goat
serum/PBS for 2 hours at 25°C. Cells were washed twice with
PBS for 5 min and incubated with a 1:1500 dilution of goat
anti-rabbit IgG flourescein-conjugated secondary antibody for
2 hours and then washed. The primary antibody was omitted
to control for nonspecific staining. Cells were incubated with
1 ml of a 1:1000 dilution of DAPI in methanol for 15 min at
37°C for nuclear staining. Coverslips were mounted with 50 µl
Fluoromount G (Electron Microscopy Sciences, Hatfield, PA,
USA). Cells were visualized using an Olympus IX70 inverted
microscope and a Photometrics Quantix camera at 100×
magnification. Images were deconvolved using a Silicon
Graphics O2 computer with DeltaVision software. Represent-
ative z stack images are shown.
Reverse transcription polymerase chain reaction
Regulation of several genes was confirmed by RT-PCR. Y and
Y-AR cells were placed in 5% twice DCC-stripped serum
overnight, treated with appropriate doses of EtOH, R5020,
progesterone, MPA and DHT for 6 or 12 hours, and harvested
for RNA (Rneasy Midi Kit, Qiagen). cDNA was synthesized
from independent total RNA [8]. Samples were resolved on
2% agarose gels and stained with ethidium bromide. GAPDH
(glyceraldehyde-3-phosphate dehydrogenase) was run as an
internal control [9]. Primer sets are as described in Table 1.
Results
Synthetic progestins and progesterone receptor
Historically, synthetic progestins were developed based on
the similarity of their biologic actions to those of progesterone
[7]. Figure 1 shows the chemical structure of progesterone
and those of its steroidal 17α-hydroxyprogesterone deriva-
tives MPA and R5020, which are used clinically and experi-
mentally, respectively. Also shown is the structure of the
androgen DHT [7].
The transcriptional activity of metabolizable progesterone,
when given every 6 hours, is identical to that of 24 hours of
nonmetabolizable R5020 (not shown). We therefore initially
used 24 hours of R5020 as the standard against which to
compare 24 hours of MPA for in vitro transcription assays.
Wild-type T47Dco breast cancer cells endogenously express-
ing PR-A and PR-B were transfected with a PRE2/luciferase
construct and treated with increasing concentrations of
R5020, MPA, or DHT. Figure 2a shows approximately equiva-
lent transcriptional activities by R5020 and MPA at all except
the 1000 nmol/l dose. DHT had little activity on PR except at
the 1000 nmol/l dose.
Although wild-type HeLa cervical cancer cells are both PR and
AR negative, T47D-Y (PR-negative) cells did express low lev-
els of endogenous AR by western blot. However, the AR were
not functional, based on transcription assays with MPA or
DHT, and by RT-PCR transcript expression of the androgen-
Table 1
RT-PCR primer sets
Gene ID Forward primer Reverse primer
KLK3 [72] (GenBank: NM_001468) TGCGCAAGTTCACCCTCA CCCTCTCCTTACTTCATCC
Krt4 (GenBank X07695) GTAGCTACTTCTTGATTTGGGCCTG ATAATACAGGATCTAGTGGGAGATG
CDKN1C (GenBank: NM_000076) TGAGAAGTCGTCGGGCGATGTCCCC GCCGGTTGCTGCTACATGAACGGTC
MAFB (GenBank: NM_005461) TCAAGTGCGTTCTTTAGACCAATGC CTGATGCAGGACAAATATCCACAAT
F3 (GenBank: NM_001993) CACAGAGTGTGACCTCACCGACGAG GTACTCTTCCGGTTAACTGTTCGGAvailable online http://breast-cancer-research.com/content/7/6/R1036
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responsive prostate-specific antigen (PSA) gene (not shown).
We next addressed the contribution of each PR isoform indi-
vidually in HeLa cervical and T47D-Y breast cancer cells exog-
enously expressing PR-A or PR-B, cotransfected with PRE2/
luciferase, and treated with increasing concentrations of
R5020, MPA, or DHT (Fig 2b–e). Because of differing trans-
fection efficiencies of Y cells transiently transfected with PR-A
and YB cells, a comparison of luciferase activities could only
be made between hormone treatments in the same cell line. A
mock transfected control vector exhibited no activity upon
addition of vehicle or hormone (not shown). On PR-A in HeLa
cells, MPA had equivalent activity to R5020 at physiologic
doses but higher activity at pharmacologic doses. DHT had lit-
tle to no activity on PR-A. On PR-B in HeLa cells, MPA had
transcriptional activity equivalent to or lower than that of
R5020 at all doses. DHT was active at the 1000 nmol/l dose.
In T47D-Y cells, MPA had lower transcriptional activity at all
doses through both PR-A and PR-B, at least on this synthetic
promoter. DHT exhibited no transcriptional activity through
PR-A but had some activity through PR-B.
Expression profiling of acute progesterone versus 
medroxyprogesterone acetate in progesterone receptor-
positive breast cancer cells
To evaluate in detail the differences, if any, between physio-
logic concentrations of progesterone and MPA, we used
Figure 2
Transcriptional activities of MPA, R5020 and DHT under the control of PR and PR isoforms Transcriptional activities of MPA, R5020 and DHT under the control of PR and PR isoforms. (a) T47Dco breast cancer cells with wild-type equimo-
lar levels of PR-A and PR-B. T47Dco cells were transfected with PRE2/luciferase and a Renilla luciferase internal control. Cells were treated for 20 
hours with MPA, R5020, or DHT, at concentrations ranging from 0.01 to 1000 nmol/l. Luciferase activity was quantitated as a percentage of 1 µmol/
l R5020 activity. The study was performed in triplicate and data are reported as mean ± standard error. *P < 0.05, 1 µmol/l dose of hormone versus 
1 µmol/l R5020. (b) HeLa cervicocarcinoma cells stably expressing PR-A. (c) PR-negative T47D-Y breast cancer cells transiently transfected with 
PR-A. (d) HeLa cells stably expressing PR-B. (e) T47D-Y cells stably expressing PR-B. Transient transfection and transcription studies were per-
formed as described above for panel a. DHT, dihydrotestosterone; MPA, medroxyprogesterone acetate; PR, progesterone receptor.Breast Cancer Research    Vol 7 No 6    Ghatge et al.
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expression profiling (Fig. 3a) at a sufficiently early time point to
assess direct transcriptional effects of the hormones [9] while
avoiding problems of progesterone metabolism [34]. Wild-
type T47Dco breast cancer cells containing equimolar levels
of PR-A and PR-B [46] were treated with 10 nmol/l progester-
one or MPA for 6 hours. T47D-Y, a PR-negative T47Dco sub-
line, served as the control. RNA from triplicate, time-separated
data points was used for analysis of gene chips interrogating
about 47,000 human transcripts. Statistically significant 2.0-
fold regulation was chosen as the cutoff. Venn diagrams pre-
sented in Fig. 3a summarize the results.
Using a 2.0-fold cutoff, in T47Dco cells a total of 1096 (2.3%)
transcripts were found to be regulated by one or both hor-
mones. Of these, 49% were upregulated and 51% were
downregulated. Among upregulated genes, 329 (61%) were
controlled by both progesterone and MPA, with the extent of
regulation ranging between about 38-fold and 2.0-fold. Simi-
larly, among downregulated genes 257 (46%) were controlled
by both hormones, with the extent of regulation ranging from
about 14-fold to 2.0-fold. When the 2.0-fold restriction was
slightly relaxed, the extent of overlap between progesterone
and MPA was even greater. For example, of the 120 genes
regulated 2.0-fold by MPA, 60 genes were also regulated by
progesterone if a 1.5-fold cutoff was allowed.
In summary, we found remarkable congruence in genes regu-
lated by progesterone and MPA. Detailed gene lists are avail-
able in Additional file 1. These tables demonstrate that both
the gene expression profiles and extent of regulation were sim-
ilar between the hormones. The few genes regulated uniquely
by either progesterone or MPA (Fig. 3a) were regulated at
much lower levels. Note also that PR-negative T47D-Y cells
Figure 3
Expression profiles of endogenous PR-regulated genes Expression profiles of endogenous PR-regulated genes. Shown are expression profiles of PR-regulated endogenous genes in breast cancer cell 
lines, with physiological progesterone versus MPA concentrations compared. (a) Venn diagrams showing gene number per condition. PR-positive 
T47Dco cells (CO) and control PR-negative T47D-Y (Y) cells were treated with 10 nmol/l progesterone or MPA for 6 hours in triplicate, time-sepa-
rated experiments. Microarray analysis using Affymetrix U-133 2 plus gene chips, displaying about 47,000 genes, was performed. Data were ana-
lyzed using Gene Spring software and statistical analysis was conducted using a one-way analysis of variance, with P < 0.05 considered statistically 
significant for genes regulated at least 2.0-fold. Detailed tables showing complete gene lists are available as Additional files 1 and 2. (b) Dendro-
grams of PR-regulated genes showing relationships among treatment groups. Gene Spring 6.0 was used to classify all genes 'present' and all MPA- 
and progesterone-regulated genes. On the left is shown the relatedness among groups for all genes. On the right is a heat map of progestin regu-
lated genes: black = average expression; red = above average; and green = below average. Each column represents a single gene; each row is a 
cell type and treatment group. DHT, dihydrotestosterone; MPA, medroxyprogesterone acetate; PR, progesterone receptor.
Figure 4
Glucocorticoid and androgenic activity of the synthetic progestins and  Dexamethasone Glucocorticoid and androgenic activity of the synthetic progestins and 
Dexamethasone. HeLa cells (GR+, PR-, AR-) were transfected with or 
without an AR expression vector, PRE2/luciferase construct and Renilla 
control, and treated for 20 hours with 10 nmol/l MPA, R5020, DHT, or 
dexamethasone. Relative luciferase activity was measured. Stippled 
bars are GR+ cells lacking AR; grey bars are GR+ and AR+ cells. AR, 
androgen receptor; DEX, dexamethasone; DHT, dihydrotestosterone; 
GR, glucocorticoid receptor; MPA, medroxyprogesterone acetate; PR, 
progesterone receptor; RLU, relative luciferase units.Available online http://breast-cancer-research.com/content/7/6/R1036
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were included as controls and exhibited very little progestin
regulation, as was expected. We speculate that the few genes
that appear to be regulated do so via a membrane receptor
[51].
The dendrogram presented in Fig. 3b, assembled from the
sum of all MPA + progesterone regulated genes demonstrates
graphically the remarkable similarity between the two hor-
mones, which segregate PR-positive, hormone-treated cells
into a different branch from PR-positive, untreated cells. Also
of interest is the fact that hormone treatment has little effect in
the absence of PR [51] and that PR positivity, even in the
absence of hormone, alters cells sufficiently to segregate them
into a different branch of the dendrogram. This unliganded
effect of PR has been reported in detail elsewhere [52].
Synthetic progestins and glucocorticoid receptors
To ensure that the transcriptional activity observed with MPA
in T47Dco cells was not occurring through an alternate steroid
receptor, we evaluated the activity of the synthetic progestins
on GR in the presence or absence of AR (Fig. 4). GR-positive,
PR/AR-negative HeLa cells were transfected with or without
AR and treated with 10 nmol/l synthetic hormones. No activity
was seen with addition of ethanol or a vector alone control
(data not shown). Dexamethasone, a GR agonist, exhibited
equivalent robust transcriptional activity in the absence or
presence of AR, suggesting that its activity is exclusively
through endogenous GR. MPA also had weak GR activity
(about 15% that of dexamethasone) at the 10 nmol/l dose.
However, addition of AR increased the activity of MPA to lev-
els equivalent to those of DHT. No androgenic activity was
seen with R5020 or dexamethasone. Similar results would be
expected with progesterone, which has about 3% relative
binding affinity to AR [53]. T47D-Y cells, the parental cells of
the YA, YB, and Y-AR breast cancer cells, were found to con-
tain little GR mRNA based on microarray data and exhibited no
transcriptional activity when treated with dexamethasone (data
not shown), allowing us to conclude that the activity of MPA in
breast cancer cells occurs through PR and AR and not
through GR. This study confirms the slight glucocorticoid but
strong androgenic activity of MPA.
Synthetic progestins and androgen receptors
The array data (Fig. 3) showed that MPA and progesterone
have similar activity through PR, but clinically the two hor-
mones exhibit different primary and side-effect profiles [32].
We therefore next assessed the activity of MPA on AR (Fig.
5a). HeLa and T47D-Y cells were transfected with an AR
expression vector and PRE2/luciferase (a consensus binding
site for PR, AR, and GR [28-30]) and were treated with
increasing concentrations of R5020, MPA, and DHT. Figure
5a shows that, at lower doses, MPA and DHT had approxi-
mately equivalent transcriptional activity on AR in both cell
lines, and that at pharmacologic doses MPA had exceptionally
strong androgenic activity in HeLa cells. R5020 had no
androgenic activity in either cell line at all doses.
We then asked whether this androgenic activity of MPA was
promoter dependent (Fig. 5b). HeLa cells were transfected
with an AR expression vector and two different androgen
responsive promoter constructs, namely PRE2/luciferase and
MMTV/luciferase, and then treated with 10 nmol/l or 1 µmol/l
R5020, MPA, or DHT. R5020 had little or no androgenic activ-
ity at either dose on either construct. Again, on PRE2/luci-
Figure 5
Transcriptional activities of MPA, R5020, and DHT under AR control Transcriptional activities of MPA, R5020, and DHT under AR control. (a) Cells transiently expressing AR and PRE2/luciferase. AR-negative HeLa 
and T47D-Y cells were transiently transfected with an AR expression vector. Cells were cotransfected with PRE2/luciferase construct and Renilla 
control, treated with varying concentrations of MPA, R5020, or DHT for 20 hours, and luciferase activity was quantified. Data are reported as a per-
centage of 1 µmol/l DHT (which was set at 100%). *P < 0.05, 1 µmol/l dose of hormone versus 1 µmol/l DHT. (b) Androgenic activity on two differ-
ent promoter constructs. HeLa cells were transiently cotransfected with and AR expression vector and either PRE2/luciferase or MMTV/luciferase. 
Cells were treated with ethanol, or 10 nmol/l and 1 µmol/l R5020, MPA, or DHT for 20 hours, and relative luciferase activity was measured. AR, 
androgen receptor; DHT, dihydrotestosterone; MPA, medroxyprogesterone acetate; PR, progesterone receptor; RLU, relative luciferase units.Breast Cancer Research    Vol 7 No 6    Ghatge et al.
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ferase MPA had higher AR activity than DHT, whereas on
MMTV/luciferase – a more complex promoter – the AR activity
of the two hormones was approximately equal.
A new, androgen receptor expressing, human breast 
cancer cell line
To better study the androgenic properties of synthetic pro-
gestins in breast cancer cells, we engineered T47D-Y cells to
stably express wild-type AR. The new cells are called Y-AR.
Figure 6a (inset) is an immunoblot showing the 110 kDa AR
protein in Y-AR cells, equivalent in size to the endogenous AR
of MCF-7 cells, which is shown for comparison. The subcellu-
lar localization of the stably expressed AR and their response
to hormone (Fig. 6B) were analyzed by confocal microscopy.
For this, AR were immunologically tagged with green fluores-
cent FITC and the nuclei labeled with DAPI. A secondary anti-
body control exhibited no nonspecific binding (not shown). In
the absence of DHT, AR were predominantly cytoplasmic.
Upon addition of DHT, AR moved to the nucleus within 2
hours and then upregulated by 20 hours. This behavior is sim-
ilar to that of wild-type AR [48,54]. A western blot was per-
formed that showed that AR levels in Y-AR cells are about the
same as in LNCaP cells and similar to PR levels in T47D cells
(data not shown).
Functional properties of the stably expressed AR when bound
by different ligands were tested in two ways: on the exoge-
nous PRE2/luciferase reporter (Fig. 6a) and by regulation of
the endogenous prostate-specific antigen transcript (Fig. 6C).
Luciferase expression was measured in Y-AR cells treated
with increasing concentrations of DHT, MPA, and R5020 (Fig.
6a). Both DHT and MPA generated equivalent maximum tran-
scription levels, with the left shift by DHT suggesting that it has
somewhat higher affinity for AR than does MPA. R5020 was
completely inactive. No transcription was observed in the
parental T47D-Y cells, which lack PR and functional AR.
Prostate-specific antigen is a marker of androgenic activity not
only in prostate but also in breast [50,55,56]. Using RT-PCR,
we assessed the ability of AR in Y-AR cells to regulate endog-
enous expression of this gene (Fig. 6c). Cells were treated for
6 or 12 hours with ethanol or hormones. Clearly, R5020 was
unable to regulate prostate-specific antigen transcript
expression, but both DHT and MPA were able to do so. Inter-
estingly, MPA is reproducibly a strong regulator of this impor-
tant androgen marker gene.
Expression profiling of medroxyprogesterone acetate 
versus dihydrotestosterone in androgen receptor-
positive breast cancer cells
To understand the androgenic effects of physiologic and high-
dose MPA, compared with those of physiologic DHT, Y-AR
cells were treated with ethanol, 10 nmol/l progesterone, MPA
or DHT, or 1 µmol/l MPA for 6 hours. Gene expression profiles
were assessed in triplicate, time-separated experiments, and
transcripts regulated at least 2.0-fold in a statistically signifi-
cant manner through AR were scored (Fig. 7a). Most genes
were upregulated. The high dose of MPA was not remarkably
Figure 6
Characterization Y-AR: a new breast cancer cell line stably expressing AR Characterization Y-AR: a new breast cancer cell line stably expressing AR. (a) AR levels and function of Y-AR. Inset: whole cell extracts of Y-AR and 
MCF-7 cells were subjected to SDS-PAGE, and proteins were transferred to nitrocellulose and probed with the anti-AR antibody PG-21 (Upstate 
Biotechnology). The 110 kDa AR band is shown. Main figure: Y-AR and control T47D-Y cells were transiently transfected PRE2/luciferase and 
treated with DHT, MPA, and R5020 at concentrations from 0.01 to 1000 nmol/l for 20 hours. Luciferase activity is shown as a percentage of 1 
mmol/l DHT (which was set at 100%). Data shown are the mean of triplicate determinations ± standard error. (b) AR immunocytochemistry in Y-AR 
cells. Y-AR breast cancer cells were treated with ethanol or 1 µmol/l DHT for 30 min, or 2 and 20 hours. ARs were immunologically visualized using 
green fluorescent FITC (row A), and the cell nucleus was labeled with blue DAPI (row B). Cells were visualized using confocal microscopy and pho-
tographed at 100×, as described in the Materials and method section. (c) PCR of the PSA transcript. RNA was harvested from Y-AR cells treated 6 
and 12 hrs with ethanol, or 1 µmol/l R5020, MPA, or DHT. RT-PCR was performed using PSA-specific primers. GAPDH is shown as a control. Rep-
resentative results are shown. AR, androgen receptor; DHT, dihydrotestosterone; EtOH, ethanol; GAPDH, glyceraldehyde-3-phosphate dehydroge-
nase; MPA, medroxyprogesterone acetate; PR, progesterone receptor; PSA, prostate-specific antigen.Available online http://breast-cancer-research.com/content/7/6/R1036
R1044
different from the low dose, with 165 genes (about 70%) reg-
ulated in common, indicating that the 10 nmol/l dose is satu-
rating the AR. Progesterone regulated few genes through AR
(not shown) in these PR-negative cells. A comparison of equal
doses (10 nmol/l) of MPA and DHT revealed that 143 genes
were regulated by both hormones, representing about 60% of
all DHT-regulated genes. Thus, MPA is an excellent androgen.
Additionally, MPA upregulated a small subset of genes that are
not DHT regulated. Similarly, DHT regulated a small subset of
genes that are not regulated by MPA. Figure 7a also shows
the downregulated genes, which represent less than 17% of
total AR regulated genes.
The regulation patterns of four genes were confirmed by RT-
PCR (Fig. 7b). Three genes upregulated by both DHT and
MPA, namely tissue factor (F3), MAF-B and KRT4, are shown
in Fig. 7b. One gene regulated only by DHT – the cyclin
dependent kinase inhibitor P57 – is also shown. No regulation
of these genes was seen in the parental Y cells, which lack
functional AR and PR.
Figure 7c summarizes the progestational versus the andro-
genic properties of physiological MPA concentrations. Of 566
genes defined as MPA upregulated, about 64% were regu-
lated through PR in T47Dco cells, about 21% through AR in
Y-AR cells, and about 15% (88 genes) in both cell lines
through both AR and PR. Slightly fewer genes (498) were
downregulated by MPA, the striking differences being the
much higher percentage of genes downregulated through PR
(98%) than through AR (3%). Thus, although MPA
upregulated and downregulated many genes via PR, the vast
majority of genes regulated by MPA via AR were upregulated
only. This is a unique finding and may reflect the ability of MPA-
bound AR to recruit coactivators preferentially; this requires
independent verification. The upregulated genes were nar-
rowed to 55 genes with regulation that was independently
confirmed (i.e. MPA regulated genes that were also regulated
by progesterone through PR, and by DHT through AR). Table
2 shows the top 33 of these dual regulated genes, arranged
by their fold regulation through MPA compared with the rele-
vant natural hormone in each cell line. Note that for each
receptor there is remarkable similarity in the fold regulation
observed using MPA compared with the natural hormone.
Thus, with regard to the AR-regulated genes, MPA is as good
an androgen as is DHT. Also of interest is the fact that, for
these dual PR/AR-regulated genes, in some cases the PR but
in others the AR were more effective. Explanations for this will
require detailed analyses of the promoters in question. The
complete table is given in Additional file 2.
Discussion
Synthetic progestins, medroxygprogesterone acetate, 
and progesterone receptor
Synthetic progestins were developed for use in oral contra-
ception and HRT. As a result they were tested for efficacy
compared with progesterone, using animal models and physi-
ologic end-points such as inhibition of ovulation and decidual-
ization of the endometrium, focused on the reproductive tract
[7]. Consequently, progestins in current clinical use tend to
resemble progesterone on the endometrium, with differences,
if any, reflecting variations in bioavailability, potency, and
metabolism [7]. However, progestins also target organs other
than the reproductive tract, including brain, breast, immune,
and gastrointestinal systems [57]. This is often reflected in dif-
ferences in their side-effect profile. For example, compared
with progesterone, MPA decreases seizure threshold [58] and
incidence of sickle cell crises [59], whereas its androgenic
effects may lead to weight gain and lipid profile alterations
[60]. Whether these side effects are mediated by PR or other
receptors is unclear. The mammary gland was rarely the sub-
ject of screening in the initial stages of pharmaceutical proges-
tin development. Nevertheless, it too is a critical target.
The impression that progesterone is an etiologic agent for
development of breast cancer is based in part on the
increased proliferative activity observed in normal breast
during the luteal phase of the menstrual cycle associated with
rising progesterone levels [61]. Whether synthetic progestins
for HRT can similarly increase breast cancer risk has been
evaluated in several studies [62,63], including the recent
Women's Health Initiative [3,6]. They show that, in comparison
with estrogens alone (including conjugated equine estro-
gens), synthetic progestins such as MPA increase breast can-
cer risk [3,6]. The present study used breast cancer models to
profile the progestational and androgenic properties of MPA,
with the goal of elucidating its gene regulatory properties. We
define 'progestational' effects as those that resemble proges-
terone and are mediated by PR, and 'androgenic' effects as
those that resemble DHT and are mediated by AR. Note that
this is an arbitrary definition. For example, in transient tran-
scription assays we observed that DHT can signal through PR-
B (Fig. 2d,e), an observation that requires further study. If this
is indeed the case, then one could argue that this effect of
DHT through PR is also 'androgenic'.
The results of our transcriptional assays suggest varying tran-
scriptional effects of hormone in different tissues and with
expression of one or both isoforms of PR. The relevance of PR
isoform expression in breast cancer has only recently been
appreciated [26,64]. Although the present study utilized
breast cancer cells that coexpress PR, as is the case in normal
breast and in the majority of breast cancers, studies in breast
cancer cells expressing only one PR isoform are in progress.
We hypothesize that the increase in luciferase activity in cervi-
cal cancer compared with breast cancer cells may reflect
varying levels of coactivators/corepressors in each tissue, as
was demonstrated by Liu and coworkers [65]. In addition, the
increased transcriptional activity in wild-type PR-A and PR-B
containing cells compared with cells containing only oneBreast Cancer Research    Vol 7 No 6    Ghatge et al.
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Figure 7
Expression profile of AR regulated genes Expression profile of AR regulated genes. Shown are expression profiles of AR-regulated genes, with physiologic DHT versus physiologic and phar-
macologic MPA concentrations in Y-AR cells compared. (a) Venn diagram comparing the number of genes regulated at least 2.0-fold by low-dose 
DHT versus low and high dose MPA. Y-AR cells were treated with ethanol, or 10 nmol/l progesterone, MPA, or DHT, or 1 µmol/l MPA for 6 hours in 
triplicate, time separated experiments. RNA was extracted, derivatized, and used to probe Affymetrix U-133 2 plus gene chips interrogating about 
47,000 genes. Data were analyzed using Gene Spring software, and statistical analysis was performed using a one-way analysis of variance, with P 
< 0.05 considered statistically significant for genes regulated at least 2.0-fold. (b) Confirmation of the hormonal regulation of four genes identified in 
panel a. Four genes shown to be hormone regulated in Y-AR cells (i.e. F3, Maf-B, Krt4 and p57) were chosen for further analysis. Bar graphs: the 
hormonal regulation of the four selected transcripts in Y-AR cells, as assessed by microarray profiling. RT-PCR: Y-AR cells were treated for 6 hours 
with ethanol, 10 nmol/l progesterone, MPA, or DHT, or 1 µmol/l MPA and RNA was isolated. Primers directed against the transcripts of the four 
selected genes were used in RT-PCR reactions, and GAPDH was run as an internal control. (c) Venn diagrams showing number and overlap of 
genes regulated by 10 nmol/l MPA in AR+ Y-AR cells versus PR+ T47D cells. Microarray and data analysis were performed as described for Fig. 3a 
(PR+, AR- cells) and panel a above (AR+, PR- cells), and data for low-dose MPA in the two cell lines were compared. The 88 genes regulated by MPA 
through either PR or AR were tabulated (Additional files 1 and 2). The top ranking genes are shown in Table 1. AR, androgen receptor; DHT, dihy-
drotestosterone; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; MPA, medroxyprogesterone acetate; PR, progesterone receptor.Available online http://breast-cancer-research.com/content/7/6/R1036
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Table 2
Top 33 dual regulated genes
GenBank ID AR PR Description
MPA DHT MPA P
NM_005627 67.53 51.80 23.33 29.48 Serum/glucocorticoid regulated kinase
AI985987 31.45 33.87 6.39 11.72 Sodium channel, nonvoltage-gated 1, gamma
AI492388 26.17 11.44 37.57 31.08 ti27d10.x1 NCI_CGAP_Kid11 Homo sapiens cDNA clone IMAGE:2131699 3', mRNA sequence.
AV707102 11.91 11.13 4.23 4.04 Pyruvate dehydrogenase kinase, isoenzyme 4
NM_004117 11.10 9.08 3.15 3.21 FK506 binding protein 5
AL556438 10.88 11.23 4.77 3.14 TCDD-inducible poly(ADP-ribose) polymerase
AA404269 8.33 7.36 6.22 5.29 Prickle-like 1 (Drosophila)
AB018580 7.54 5.38 4.74 4.69 Aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid dehydrogenase, type II)
NM_005461 6.82 11.65 15.98 15.80 v-maf musculoaponeurotic fibrosarcoma oncogene homolog B (avian)
NM_001993 6.76 6.39 20.32 12.77 Coagulation factor III (thromboplastin, tissue factor)
NM_001992 6.01 5.99 4.61 2.84 Coagulation factor II (thrombin) receptor
BE219979 5.82 8.07 12.62 12.49 Interleukin 20 receptor, alpha
NM_019018 5.06 4.63 8.18 8.43 Hypothetical protein FLJ11127
NM_006096 4.63 4.34 10.19 10.50 N-myc downstream regulated gene 1
NM_012429 4.42 4.95 4.06 3.76 SEC14-like 2 (S. cerevisiae)
W86302 4.22 3.96 2.58 2.68 FK506 binding protein 5
AF288571 4.07 3.95 2.91 3.38 Lymphoid enhancer-binding factor 1
AW135013 4.00 8.54 16.37 13.28 v-maf musculoaponeurotic fibrosarcoma oncogene homolog B (avian)
BF593382 3.71 3.53 2.16 2.27 Protein kinase, AMP-activated, beta 2 non-catalytic subunit
AF131840 3.61 4.13 3.87 3.14 SPRY domain-containing SOCS box protein SSB-1
AA721025 3.47 3.00 5.59 3.30 Homo sapiens transcribed sequence with moderate similarity to protein ref:NP_060265.1 (H.sapiens)
AI753747 3.32 3.23 2.46 2.22 FK506 binding protein 5
N73742 3.31 3.18 3.73 3.45 Homo sapiens cDNA FLJ42287 fis, clone TLIVE2005866
AA037766 3.27 2.81 3.17 2.56 Homo sapiens LOC374963 (LOC374963), mRNA
AL357503 3.17 4.55 8.33 8.02 Match: proteins: Tr:Q9UJ12 Tr:O43723 Tr:Q9VZN3
NM_004235 3.06 4.89 4.69 4.83 Kruppel-like factor 4 (gut)
BI668074 3.06 4.81 2.52 2.36 603295907F1 NIH_MGC_96 Homo sapiens cDNA
AL562398 2.82 2.24 2.12 2.14 AL562398 Homo sapiens NEUROBLASTOMA COT 25-NORMALIZED
BG150485 2.78 2.88 2.79 2.03 Solute carrier family 6 (neurotransmitter transporter, taurine), member 6
BF056282 2.77 2.43 2.33 2.18 Chromosome 9 open reading frame 52
BF514079 2.73 4.33 8.09 7.66 Kruppel-like factor 4 (gut)
Shown are the top genes and their fold upregulation in Y-AR (AR+) and T47D (PR+) cells treated with physiologic concentrations of MPA and 
either DHT or progesterone. AR, androgen receptors; DHT, dihydrotestosterone; MPA, medroxyprogesterone acetate; P, progesterone; PR, 
progesterone receptor.Breast Cancer Research    Vol 7 No 6    Ghatge et al.
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receptor may reflect the additional contribution of the PR-A/
PR-B dimer to transcription.
Here we addressed the global gene regulatory properties of
MPA in comparison with those of progesterone in wild-type
cells that express equimolar levels of PR-A and PR-B. We
found that approximately equal numbers of genes are down-
regulated and upregulated by each progestin. Because previ-
ous studies [8,9] assessing the contributions of individual PR
isoforms reported more upregulated genes, the present
finding may represent the contribution of the PR heterodimer
to gene regulation. We found that almost all transcripts regu-
lated by progesterone were also regulated by MPA, and in
most cases that regulatory levels were approximately equal,
with some transcript levels altered more extensively by MPA
than by progesterone. Although a few genes appeared to be
uniquely MPA regulated, their regulation was weak and the
significance of this, if any, requires further study. PR-negative
T47D-Y cells were tested as a negative control. Very few
genes (about 25) were regulated by the progestins in these
cells, and we speculate that this may represent actions of
alternate steroid receptors such as GR or perhaps membrane-
bound PR [51]. Overall, we conclude that with regard to PR,
MPA may be a somewhat more potent but otherwise
qualitatively similar progestin to progesterone. Its clinical value
lies in its resistance to metabolism and more stable pharma-
cokinetics as compared with progesterone [32]. In studies to
be reported elsewhere, we found similarly that several other
synthetic progestins in clinical use have expression profiles
resembling progesterone [66].
Androgenicity of medroxyprogesterone acetate
In addition, our studies clearly indicate that, unlike progester-
one, MPA is a potent androgen in breast cancer cells. In Y-AR
cells treated with 0.1 nmol/l DHT or MPA, we also found that
the androgenic activity of both hormones is 80–90% inhibita-
ble by the antiandrogen bicalutamide (10 µmol/l; data not
shown). That MPA has androgenic activity has been sus-
pected based on its side-effect profile in other organs [67] at
the low concentrations used for oral contraception and HRT.
With regard to normal breast, epithelial cells express estrogen
receptor (ER), PR and AR, but adjacent myoepithelial cells and
stroma express none of the three steroid receptors [68]. In
malignancy, grade 1 and 2 ductal carcinoma in situ express
ER, PR and AR, whereas the majority of grade 3 ductal carci-
noma in situ are ER and PR negative but continue to be AR-
positive [68]. Lea and coworkers [69] quantitated AR by
immunohistochemistry in 1026 metastatic tumors and found
that AR were present at double the frequency of PR. In fact, in
one out of four tumors AR are expressed as the sole sex hor-
mone receptor. The expression of AR in ER-negative tumors is
associated with a better disease-free survival [70]. In this
regard, it is interesting that addition of testosterone to stand-
ard estrogen or estrogen + progesterone therapy reportedly
reduces the risk associated with HRT to that of the untreated
population [71]. Thus, the expression and activation of AR may
play an important role in the development of breast cancers
and response to hormone therapies.
The data presented here show that, in human breast cancer
cells, physiologic doses of MPA elicit as good an androgenic
response as DHT and as good a progestational response as
progesterone. We would conclude that at the physiologic
doses used for oral contraception and HRT, MPA delivers a
powerful androgenic outcome. However, MPA is often given at
pharmacologic doses, such as when it is used as a second-
line agent for the treatment of metastatic breast cancer and for
treatment of early endometrial cancer [39]. Numerous investi-
gators have suggested that the efficacy of MPA at pharmaco-
logic doses in breast cancer treatment is due to activation of
AR rather than PR at those doses [37]. Based on our data (Fig.
7a), we would argue that high-dose MPA is no different from
low dose MPA. This makes sense if physiologic concentra-
tions suffice to saturate both PR and AR, in which case higher
concentrations would not be expected to have further effects.
Indeed, our data clearly show that increasing the dose of MPA
does not alter its transcriptional profile. Based on this we
would argue that there is no rationale for using high-dose MPA
for any indication, and suggest that lower doses might suffice
for treatment of endometrial and breast cancers. If lower doses
are indeed sufficient, then the administration of high doses
may only exacerbate side effects without improving the thera-
peutic index. Further studies evaluating the use of lower doses
of MPA in treatment of AR-positive breast cancers would be of
interest.
There was some overlap (Fig. 7c) among genes upregulated
by MPA in vivo through both PR and AR. As we define them,
these are 55 genes upregulated by progesterone through PR,
and by DHT through AR, with MPA having the ability to acti-
vate both sets. We suggest that this blurs the boundaries
between androgenic and progestational effects. Further
analysis of the promoter sequences and tissue distributions of
these 55 genes may suggest a pattern of regulation that
allows selective activation by only one receptor in vivo.
Alternatively, these may be key genes that evolved in both
males and females, for regulation by androgens or progester-
one, respectively. In summary, more genes are regulated (both
up and down) by MPA through PR than through AR. Interest-
ingly, there are genes regulated by DHT that are not regulated
by MPA (Fig. 7a). The mechanisms underlying this differential
effect also require study. One of these genes is p57, a cyclin-
dependent kinase inhibitor with activity that suggests a
possible mechanism for inhibition of cell cycle regulation and
proliferation by AR in breast cancers.
Conclusion
The finding that physiologic MPA is both a potent progestin
and androgen in the same cell type has important implications
for women's health. The strong androgenic effects of MPAAvailable online http://breast-cancer-research.com/content/7/6/R1036
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when compared with progesterone suggest that physiologic
hormone replacement using progestins such as MPA in HRT
do not mimic the actions of endogenous progesterone alone.
Our data suggest that the findings of the Women's Health Ini-
tiative may represent the dual action of MPA on PR and AR.
The studies described here are limited to short term treat-
ments in vitro, with the limitations thereof. We have begun to
investigate the effects of long-term MPA treatment using the
new Y-AR breast cancer cells growing as xenografts in nude
mice to test further our hypothesis that the activity of MPA in
the breast is mediated through its dual function as a progestin
and androgen.
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